Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2)

British Journal of Pharmacology

Volumn 148, Issue 8, 2006, Pages 1051-1059

  Langer, Ingrid ^a   Gaspard, Nathalie ^a   Robberecht, Patrick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

cAMP; Coexpression; Receptor internalization; Selective agonist; Vasoactive intestinal peptide; VPAC1; VPAC2

Indexed keywords

ADENYLATE CYCLASE; DIMER; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR[8-27]; LIGAND; MONOCLONAL ANTIBODY; RECOMBINANT RECEPTOR; RO 251553; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VASOACTIVE INTESTINAL POLYPEPTIDE[1-7][15 LYSINE 16 ARGININE 21 LEUCINE];

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHO CELL; DIMERIZATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; IMMUNOPRECIPITATION; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

ADENYLATE CYCLASE; ANIMALS; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCYTOSIS; ENZYME ACTIVATION; HUMANS; IMMUNOPRECIPITATION; RADIOLIGAND ASSAY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I;

EID: 33747143082     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706816     Document Type: Article

References (34)

1. ABDALLA, S., LOTHER, H., ABDEL-TAWAB, A.M. & QUITTERER, U. (2001). The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem., 276, 39721-39726.
2. AKESSON, L., AHREN, B., EDGREN, G. & DEGERMAN, E. (2005). VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology, 146, 744-750.
3. BALLESTEROS, J.A., SHI, L. & JAVITCH, J.A. (2001). Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol., 60, 1-19.
4. BUSTO, R., PRIETO, J.C., BODEGA, G., ZAPATERO, J. & CARRERO, I. (2000). Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides, 21, 265-269.
5. DELGADO, M., DE LA, F.M., MARTINEZ, C. & GOMARIZ, R.P. (1995). Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. J. Neuroimmunol., 62, 137-146.
6. DELGADO, M. & GANEA, D. (2001). Vasoactive intestinal peptide and pituitary adenylate cyclase- activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. J. Immunol., 166, 1028-1040.
7. DELGADO, M., POZO, D. & GANEA, D. (2004). The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev., 56, 249-290.
8. DING, W.Q., CHENG, Z.J., MCELHINEY, J., KUNTZ, S.M. & MILLER, L.J. (2002). Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res., 62, 5223-5229.
9. GARCIA-FERNANDEZ, M.O., SOLANO, R.M., CARMENA, M.J., BUSTO, R., BODEGA, G., RUIZ-VILLAESPESA, A., PRIETO, J.C. & SANCHEZ-CHAPADO, M. (2003). Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides, 24, 893-902.
10. GEORGE, S.R., FAN, T., XIE, Z., TSE, R., TAM, V., VARGHESE, G. & O'DOWD, B.F. (2000). Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem., 275, 26128-26135.
11. GETHER, U. & KOBILKA, B.K. (1998). G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem., 273, 17979-17982.
12. GOURLET, P., VANDERMEERS, A., VERTONGEN, P., RATHE, J., DE NEEF, P., CNUDDE, J., WAELBROECK, M. & ROBBERECHT, P. (1997a). Development of high affinity selective VIP1 receptor agonists. Peptides, 18, 1539-1545.
13. GOURLET, P., VERTONGEN, P., VANDERMEERS, A., VANDERMEERS-PIRET, M.C., RATHE, J., DE NEEF, P., WAELBROECK, M. & ROBBERECHT, P. (1997b). The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides, 18, 403-408.
14. HARIKUMAR, K.G., MORFIS, M.M., LISENBEE, C.S., SEXTON, P.M. & MILLER, L.J. (2006). Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol. Pharmacol., 69, 363-373.
15. HARMAR, A.J., ARIMURA, A., GOZES, I., JOURNOT, L., LABURTHE, M., PISEGNA, J.R., RAWLINGS, S.R., ROBBERECHT, P., SAID, S.I., SREEDHARAN, S.P., WANK, S.A. & WASCHEK, J.A. (1998). International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase- activating polypeptide. Pharmacol. Rev., 50, 265-270.
16. JONES, K.A., BOROWSKY, B., TAMM, J.A., CRAIG, D.A., DURKIN, M.M., DAI, M., YAO, W.J., JOHNSON, M., GUNWALDSEN, C., HUANG, L.Y., TANG, C., SHEN, Q., SALON, J.A., MORSE, K., LAZ, T., SMITH, K.E., NAGARATHNAM, D., NOBLE, S.A., BRANCHEK, T.A. & GERALD, C. (1998). GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature, 396, 674-679.
17. JUARRANZ, M.G., BOLANOS, O., GUTIERREZ-CANAS, I., LERNER, E.A., ROBBERECHT, P., CARMENA, M.J., PRIETO, J.C. & RODRIGUEZ-HENCHE, N. (2001). Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal., 13, 887-894.
18. LANGER, I., PERRET, J., VERTONGEN, P., WAELBROECK, M. & ROBBERECHT, P. (2001). Vasoactive intestinal peptide (VIP) stimulates [Ca(2+)](i)and cyclic AMPin CHO cells expressing Galpha16. Cell Calcium, 30, 229-234.
19. LANGLET, C., GASPARD, N., NACHTERGAEL, I., ROBBERECHT, P. & LANGER, I. (2004). Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells. Peptides, 25, 2079-2086.
20. LANGLET, C., LANGER, I., VERTONGEN, P., GASPARD, N., VANDERWINDEN, J.M. & ROBBERECHT, P. (2005). Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling. J. Biol. Chem., 280, 28034-28043.
21. LAVOIE, C., MERCIER, J.F., SALAHPOUR, A., UMAPATHY, D., BREIT, A., VILLENEUVE, L.R., ZHU, W.Z., XIAO, R.P., LAKATTA, E.G., BOUVIER, M. & HEBERT, T.E. (2002). Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem., 277, 35402-35410.
22. LEE, S.P., SO, C.H., RASHID, A.J., VARGHESE, G., CHENG, R., LANCA, A.J., O'DOWD, B.F. & GEORGE, S.R. (2004). Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem., 279, 35671-35678.
23. MILLIGAN, G. (2004). G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol., 66, 1-7.
24. PANKHANIYA, R., JABRANE-FERRAT, N., GAUFO, G.O., SREEDHARAN, S.P., DAZIN, P., KAYE, J. & GOETZL, E.J. (1998). Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J., 12, 119-127.
25. PFEIFFER, M., KOCH, T., SCHRODER, H., KLUTZNY, M., KIRSCHT, S., KREIENKAMP, H.J., HOLLT, V. & SCHULZ, S. (2001). Homo-and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem., 276, 14027-14036.
26. PIERCE, K.L., PREMONT, R.T. & LEFKOWITZ, R.J. (2002). Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol., 3, 639-650.
27. PRINSTER, S.C., HAGUE, C. & HALL, R.A. (2005). Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol. Rev., 57, 289-298.
28. SALAHPOUR, A., ANGERS, S., MERCIER, J.F., LAGACE, M., MARULLO, S. & BOUVIER, M. (2004). Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J. Biol. Chem., 279, 33390-33397.
29. SALOMON, Y., LONDOS, C. & RODBELL, M. (1974). A highly sensitive adenylate cyclase assay. Anal. Biochem., 58, 541-548.
30. SCHULZ, S., ROCKEN, C., MAWRIN, C., WEISE, W., HOLLT, V. & SCHULZ, S. (2004). Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin. Cancer Res., 10, 8235-8242.
31. SECK, T., BARON, R. & HORNE, W.C. (2003). The alternatively spliced deltae13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression. J. Biol. Chem., 278, 23085-23093.
32. TERRILLON, S., BARBERIS, C. & BOUVIER, M. (2004). Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc. Natl. Acad. Sci. U.S.A, 101, 1548-1553.
33. TERRILLON, S. & BOUVIER, M. (2004). Roles of G-protein-coupled receptor dimerization. EMBO Rep., 5, 30-34.
34. TERRILLON, S., DURROUX, T., MOUILLAC, B., BREIT, A., AYOUB, M.A., TAULAN, M., JOCKERS, R., BARBERIS, C. & BOUVIER, M. (2003). Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol., 17, 677-691.